Last 10.65 NOK
Change Today +0.15 / 1.43%
Volume 16.9K
NAVA On Other Exchanges
Symbol
Exchange
Berlin
As of 10:25 AM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

navamedic (NAVA) Snapshot

Open
10.15 NOK
Previous Close
10.50 NOK
Day High
10.65 NOK
Day Low
10.15 NOK
52 Week High
02/24/14 - 16.30 NOK
52 Week Low
01/28/15 - 10.15 NOK
Market Cap
91.2M
Average Volume 10 Days
16.3K
EPS TTM
0.08 NOK
Shares Outstanding
8.6M
EX-Date
05/7/12
P/E TM
131.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for NAVAMEDIC (NAVA)

Related News

No related news articles were found.

navamedic (NAVA) Related Businessweek News

No Related Businessweek News Found

navamedic (NAVA) Details

Navamedic ASA, a pharmaceutical company, in-licenses, buys, and markets pharmaceuticals and other health care products in Norway and internationally. Its product portfolio includes original and generic pharmaceuticals, as well as food supplements, medical devices, and other health care products. The company also distributes medical nutrition products for various metabolic disorders, including phenylketonuria, tyrosinemia, maple sirup urine disease, homocystinuria, methylmalonic acidemia, propionic acidemia, and glutaric aciduria type 1, as well as carbohydrate metabolism, fat metabolism, and renal diseases. In addition, it sells consumer care products, including non-prescription pharmaceuticals primarily through pharmacies and/or drugstores. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was founded in 2002 and is headquartered in Lysaker, Norway.

Founded in 2002

navamedic (NAVA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

navamedic (NAVA) Key Developments

Navamedic ASA Reports Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Navamedic ASA reported consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, operating revenues were NOK 58,769,000 against NOK 36,722,000 for the same period in the last year. EBITDA was NOK 4,205,000 against NOK 821,000 for the same period in the last year. Operating results (EBIT) was NOK 1,910,000 against NOK 221,000 for the same period in the last year. Ordinary results before tax were NOK 1,880,000 against NOK 476,000 for the same period in the last year. Net profit was NOK 1,519,000 against net loss of NOK 936,000 for the same period in the last year. Net cash flow used in operations was NOK 11,802,000 against NOK 11,802,000 for the same period in the last year. Purchase of intangible assets was NOK 185,000. Diluted earnings per share were NOK 0.18 against diluted loss per share of NOK 0.11 for the same period in the last year. For the nine months, operating revenues were NOK 161,125,000 against NOK 108,852,000 for the same period in the last year. EBITDA was NOK 9,209,000 against NOK 5,124,000 for the same period in the last year. Operating result (EBIT) was NOK 3,043,000 against operating loss of NOK 55,000 for the same period in the last year. Ordinary result before tax was NOK 2,335,000 against ordinary loss before tax was NOK 747,000 for the same period in the last year. Net profit was NOK 1,931,000 against net loss of NOK 31,000 for the same period in the last year. Net cash out flow from operations was NOK 11,249,000 against NOK 14,618,000 for the same period in the last year. Purchase of intangible assets was NOK 813,000 against NOK 1,900,000 for the same period in the last year. Diluted earnings per share were NOK 0.23.

Navamedic ASA to Report Q3, 2014 Results on Oct 31, 2014

Navamedic ASA announced that they will report Q3, 2014 results on Oct 31, 2014

Navamedic ASA Includes Antithrombotic Drug Arixtra in its Product Portfolio

Navamedic ASA announced that the company has included the antithrombotic drug Arixtra in its product portfolio. The product has a EUR 1 million sales potential in the Nordic markets. Arixtra is primarily used by hospitals to prevent blood from clotting during and after heart and coronary artery surgery. Navamedic assumes distribution of Arixtra in the Nordic markets, following the Company's expanded co-operation with pharmaceutical manufacturer Aspen of South Africa.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NAVA:NO 10.65 NOK +0.15

NAVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NAVA.
View Industry Companies
 

Industry Analysis

NAVA

Industry Average

Valuation NAVA Industry Range
Price/Earnings 100.0x
Price/Sales 0.4x
Price/Book 0.7x
Price/Cash Flow 9.1x
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NAVAMEDIC, please visit www.navamedic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.